Device Trial Radar · NCT00234559
Trial of Vacuum Assisted Closure® Therapy Versus Control Therapy in Angiogenesis
Last checked: Nov 20, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 2005
Primary completion
Aug 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- KCI USA, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 7, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine: 1. If vacuum assisted closure (VAC®) therapy results in altered proteomic expression of angiogenic markers compared to moist wound therapy. 2. If VAC® therapy results in increased angiogenesis compared to moist wound therapy.
Conditions
- Wounds
Interventions
VAC® Therapy SystemDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Altered proteomic expression evaluated by angiogenic markers using biomolecular assays of biopsy samples at Day 0, Day 3, Day 7, Day 21, and Day 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.